Cervical Cancer News and Research

RSS

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

Bivalent HPV vaccine efficacy may be independent of dose

Fewer than three doses of the bivalent human papillomavirus vaccine may be sufficient to offer adequate protection against cervical HPV-16 and -18 infection, research published in The Lancet Oncology indicates.

17 Jun 2015

Nanoplatform technology that detects early stages of cancer receives U.S. patent

A U.S. patent has been awarded to a Kansas State University technology that quickly detects the early stages of cancer before physical symptoms ever appear.

17 Jun 2015

CINtec PLUS Cytology test more effective than HC2 HPV test in identifying women with precancerous lesions

Ventana Medical Systems, Inc., a member of the Roche Group, today announced the publication of further results from the Primary ASC-US LSIL Marker Study (PALMS) in this month's issue of Cancer Cytopathology. The PALMS study, which enrolled more than 27,000 women from five European countries, was designed to evaluate the diagnostic performance of the CINtec PLUS Cytology test in detecting pre-cancerous cervical disease compared to HPV testing and more traditional screening methods like Pap cytology.

16 Jun 2015

Genticel’s GTL001 phase 1 clinical study of HPV therapeutic vaccine granted FDA clearance

Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel’s Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.

16 Jun 2015

Keele University academic calls for urgent review of cervical screening programmes

As Cervical Screening Awareness Week begins, a Keele University academic is calling for cervical screening programmes and perceptions of cervical cancer to be reviewed urgently, to encourage more older women to get regularly screened.

15 Jun 2015

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor, Weill Cornell Medical College scientists report today. But a therapy that restores the cells' disease-fighting abilities could provide a powerful new strategy to attack the cancer, which kills more than 14,000 women each year.

12 Jun 2015

Nearly 15 million U.S. women have limited access to specialized gynecologic cancer care

More than one-third of counties in the Unites States are located more than 50 miles from the nearest gynecologic oncologist, making access to specialty care for ovarian and other gynecologic cancers difficult for nearly 15 million women. While most of these "low access" counties are located in the Mountain-West and Midwest regions, the findings of a recent study from researchers at the Perelman School of Medicine at the University of Pennsylvania also reveal that 47 states have at least one county located more than 50 miles from the nearest gynecologic oncologist.

12 Jun 2015

New study shows that estrogen receptors vanish in cervical cancer tumors

Scientists have prior evidence that the hormone estrogen is a major driver in the growth of cervical cancer, but a new study examining genetic profiles of 128 clinical cases reached a surprising conclusion: Estrogen receptors all but vanish in cervical cancer tumors.

10 Jun 2015

Single dose of Cervarix vaccine effective in preventing HPV infections

A single dose of the human papillomavirus (HPV) vaccine Cervarix appears to be as effective in preventing certain HPV infections as three doses, the currently recommended course of vaccination.

10 Jun 2015

Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Although there is no one established universal cause of cancer, genetic changes are central to its development. The accumulation of spontaneous genetic changes, or mutations, that occur when cells divide can be hastened by exposure to carcinogens such as cigarette smoke (lung cancer) and infectious agents such as the papillomavirus (cervical cancer).

9 Jun 2015

Chronic exposure to bacteria may lead to development of Type 2 diabetes

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers (H. pylori bacteria).

2 Jun 2015

Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), announces today positive preclinical in vivo proof of concept results of GTL002, its multivalent HPV therapeutic vaccine candidate based on the Company’s versatile Vaxiclase platform.

2 Jun 2015

FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer.

1 Jun 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from five studies that demonstrate the clinical utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in helping to identify targeted treatment options for patients with rare and/or aggressive tumors.

1 Jun 2015

MedUni Vienna expert suggests pricing strategy to reduce smoking

30% of the estimated 2.3 million smokers in Austria are considered to be heavily tobacco-dependent and, according to experts at MedUni Vienna, require professional treatment. This would mean around 690,000 people. According to Michael Kunze, an expert on smoking at the Center for Public Health at MedUni Vienna, an effective strategy would be to increase the price of tobacco products: "If the price of cigarettes were to rise just one percent above the inflation rate, that would bring about a 0.5% reduction in consumption worldwide."

29 May 2015

Study: New cases of cancer rising globally, but death rates falling in many countries

New cases of virtually all types of cancer are rising in countries globally - regardless of income - but the death rates from cancer are falling in many countries, according to a new analysis of 28 cancer groups in 188 countries.

29 May 2015

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients.

28 May 2015

Study shows trophon EPR effective in inactivating high-risk, cancer-causing HPV

A new study presented at the Society for Healthcare Epidemiology of America has demonstrated that the trophon EPR is the only high level disinfection system proven to kill natural, infectious, high-risk human papilloma virus (HPV) under normal use conditions.

20 May 2015

Study shows trophon EPR effective in inactivating high-risk, cancer-causing HPV

20 May 2015

Uninsured, low-income women in non-expansion states less likely to receive breast, cervical cancer screenings

Virginia Commonwealth University Massey Cancer Center researchers recently conducted a study that found low-income and uninsured women in states that are not expanding their Affordable Care Act (ACA) Medicaid coverage are less likely to receive breast and cervical cancer screenings compared to states that are implementing expansions.

14 May 2015

Cervical Cancer News and Research

Further Reading

Bivalent HPV vaccine efficacy may be independent of dose

Nanoplatform technology that detects early stages of cancer receives U.S. patent

CINtec PLUS Cytology test more effective than HC2 HPV test in identifying women with precancerous lesions

Genticel’s GTL001 phase 1 clinical study of HPV therapeutic vaccine granted FDA clearance

Keele University academic calls for urgent review of cervical screening programmes

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Nearly 15 million U.S. women have limited access to specialized gynecologic cancer care

New study shows that estrogen receptors vanish in cervical cancer tumors

Single dose of Cervarix vaccine effective in preventing HPV infections

Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Chronic exposure to bacteria may lead to development of Type 2 diabetes

Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

MedUni Vienna expert suggests pricing strategy to reduce smoking

Study: New cases of cancer rising globally, but death rates falling in many countries

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

Study shows trophon EPR effective in inactivating high-risk, cancer-causing HPV

Study shows trophon EPR effective in inactivating high-risk, cancer-causing HPV

Uninsured, low-income women in non-expansion states less likely to receive breast, cervical cancer screenings

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News